Titlebook: New Rapid-acting Antidepressants; Kenji Hashimoto,Mario Manto Book 2021 The Editor(s) (if applicable) and The Author(s), under exclusive l

水平

書目名稱New Rapid-acting Antidepressants影響因子(影響力)




書目名稱New Rapid-acting Antidepressants影響因子(影響力)學科排名




書目名稱New Rapid-acting Antidepressants網(wǎng)絡公開度




書目名稱New Rapid-acting Antidepressants網(wǎng)絡公開度學科排名




書目名稱New Rapid-acting Antidepressants被引頻次




書目名稱New Rapid-acting Antidepressants被引頻次學科排名




書目名稱New Rapid-acting Antidepressants年度引用




書目名稱New Rapid-acting Antidepressants年度引用學科排名




書目名稱New Rapid-acting Antidepressants讀者反饋




書目名稱New Rapid-acting Antidepressants讀者反饋學科排名

承認

New Rapid-acting Antidepressants978-3-030-79790-4Series ISSN 2627-535X Series E-ISSN 2627-5341

做事過頭

Kenji Hashimoto,Mario MantoDiscusses new candidate for rapid-acting antidepressants.Provides information for those who work in the field of CNS drugs.Ideal for pharmacologists, psychiatrists, and those who want to learn about C

Ledger

儀式

https://doi.org/10.1007/978-3-030-79790-4Glutamate receptor; NMDA receptor; mGluR receptor; GABA receptor; Muscarinic receptor; IL-6 antibody

Archipelago

(,)-Ketamine: A New Rapid-Acting Antidepressant,ecise molecular and cellular mechanisms underlying the antidepressant effects of (.)-ketamine are unclear, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor activation may have a role in its antidepressant actions. In addition, inflammatory bone markers, extracellular-signal-regulated ki

裂隙

Novel AMPA Receptor Potentiators TAK-137 and TAK-653 as Potential Rapid-Acting Antidepressants,tivity. In this chapter, I will describe our strategy for discovering AMPA-R potentiators with lower agonistic activity. I will also review the in vitro and in vivo profiles of TAK-137 and TAK-653, including their procognitive and antidepressant-like effects.

travail

AMPA Receptor Potentiators as Potential Rapid-Acting Antidepressants, its behavioral action is blocked by AMPAR antagonists..Moreover, the removal of specific AMPAR subunits from birth results in behavioral and neurochemical characteristics relevant to depression. Taken together, these findings suggest that the stimulation of AMPARs may be a useful approach to treat

DEAF

Abrade

Antidepressant Effects of the Muscarinic Receptor Antagonist Scopolamine: Clinical and Preclinical follow-up investigation of ketamine’s clinical profile. This chapter is an attempt to review the clinical and preclinical antidepressant data of scopolamine with a view on illuminating the critical muscarinic receptor subtype(s) that could prove fruitful as a next-generation antimuscarinic drug targ